Molecular diagnostics company Exact Sciences Corp. (NASDAQ:EXAS) announced on Friday that it has received FDA approval for its next-generation multitarget stool DNA test, Cologuard Plus.
This test is approved for adults aged 45 and older at average risk for colorectal cancer (CRC). Approval followed findings from the pivotal BLUE-C study, one of the largest prospective studies in CRC screening, involving nearly 19,000 participants.
Cologuard Plus demonstrated 95% overall cancer sensitivity and 43% sensitivity for advanced precancerous lesions at 94% specificity with no colonoscopy findings. Additionally, it significantly outperformed an independent fecal immunochemical test in various sensitivity metrics.
CRC, often preventable yet frequently undetected, remains the second deadliest cancer in the US Cologuard Plus builds on the success of the original Cologuard test, which has been utilized over 17 million times. Launching in 2025, the test will leverage Exact Sciences' commercial organization and ExactNexus technology platform, ensuring seamless integration for over 350 health systems.
Eisai completes rolling BLA submission for lecanemab-irmb to FDA
TME Pharma secures EUR2.4m grant for NOX-A12 Phase 2 trial
Satsuma Pharmaceuticals and Shin Nippon Biomedical resubmit STS101 NDA to FDA
Henlius and Organon announce FDA acceptance of BLA for denosumab biosimilar, HLX14
I-Mab announces presentation of Phase 1 dose data for givastomig at SITC 2024
Sobi to present emapalumab data for treating macrophage activation syndrome at ACR Conference
Foresee Pharmaceuticals submits US FDA New Drug Application for three-month version of CAMCEVI
Organon adds VTAMA cream to dermatology portfolio with acquisition of Dermavant
Johnson & Johnson reports strong Phase 3 results for TREMFYA in Crohn's Disease
Kind Pharmaceutical's AND017 receives US FDA Orphan Drug Designation
RiboX Therapeutics' RXRG001 Phase I/IIa Study IND application receives US FDA approval
Modalis Therapeutics receives Orphan Drug Designation for MDL-101
EpiVax and CUBRC receive USD2m contract from US FDA
U.P. Oncolytics' oncolytic virus-based therapy granted US FDA Orphan Drug designation
United Therapeutics reaches milestone with 500th lung transplant via ex vivo lung perfusion service